Big Phar­ma-part­nered clin­i­cal tri­al match­mak­er se­cures $20M to im­prove plat­form

3 years ago
Financing
Pharma

Ot­su­ka, Lund­beck eye Alzheimer's in­di­ca­tion in FDA ad­comm for Rex­ul­ti la­bel ex­pan­sion

3 years ago
Pharma
FDA+

Phar­maron ex­pand­ing Liv­er­pool man­u­fac­tur­ing fa­cil­i­ty with a $186M+ price tag

3 years ago
China
Manufacturing

Boehringer re­ports ro­bust sales led by type 2 di­a­betes and pul­monary drugs, promis­es more to come high­light­ing ...

3 years ago
Pharma
Marketing

In search of new way to de­liv­er gene ed­i­tors, CRISPR pi­o­neer turns to mol­e­c­u­lar sy­ringes

3 years ago
R&D
Discovery

Monopar puts a stop to its chemo com­pli­ca­tion drug; Ex­i­cure ex­plores fu­ture trans­ac­tions

3 years ago
News Briefing

Blue­bird to miss Q1 dead­line for lo­vo-cel fil­ing, shares sliced

3 years ago
FDA+

Lay­offs hit pri­vate gene ther­a­py star­tups, mi­graine biotech Sat­suma as in­dus­try squeeze doesn’t let up

3 years ago
People

Por­tal In­no­va­tions takes its Chica­go biotech in­vest­ing, lab space mod­el to Boston with Bob Langer start­up in tow

3 years ago
Financing
Startups

FDA ap­proves Nar­can opi­oid over­dose re­ver­sal spray for over-the-counter sale

3 years ago
Pharma
FDA+

Deer­field Dis­cov­ery nets $50M from the state of New York and par­ent com­pa­ny

3 years ago
Financing
Discovery

J&J bows out of RSV vac­cine race, end­ing PhI­II study and ced­ing to Pfiz­er, GSK

3 years ago
R&D
Pharma

No longer ‘dead or just hi­ber­nat­ing,’ drug­mak­ers re­turn to heart med­i­cines

3 years ago
R&D
In Focus

As­traZeneca ax­es li­cense agree­ment with Aridis, plac­ing Eu­rope-fund­ed PhI­II on hold

3 years ago
Deals
Pharma

Eu­ro­pean in­vest­ment group clos­es €260M raise for de­men­tia fund

3 years ago
Financing

FDA lifts par­tial hold on Blue­print­'s CDK2 in­hibitor

3 years ago
FDA+

Bio­mea goes for $125M of­fer­ing af­ter ear­ly di­a­betes da­ta near­ly dou­bled stock price

3 years ago
Financing

Van­da wins court case against FDA over dis­clo­sure of CRL de­tails for sleep drug

3 years ago
R&D

Ohio at­tor­ney gen­er­al sues sev­er­al PBMs over an­titrust con­cerns

3 years ago
Pharma
Law

House com­mit­tee chair re­quests in­fo from FDA on fund­ing for tri­als in­volv­ing 'vi­ral ma­nip­u­la­tion'

3 years ago
FDA+
Law

Phar­ma ad to­tal tops $8B again in 2022, led by top brands from Sanofi and Re­gen­eron, Ab­b­Vie

3 years ago
Pharma
Marketing

FDA plans up­com­ing ad­comms for OTC con­tra­cep­tive, ep­i­neph­rine nasal spray, Intar­ci­a's last shot

3 years ago
FDA+

House com­mit­tee to in­ves­ti­gate FDA's re­sponse to on­go­ing drug short­ages

3 years ago
Pharma
FDA+

Q&A: Pfiz­er cor­po­rate com­mu­ni­ca­tions chief Sal­ly Sus­man dis­cuss­es book craft­ed in pan­dem­ic and per­son­al lessons

3 years ago
Pharma
Marketing
First page Previous page 366367368369370371372 Next page Last page
A service from the Financial Times